NCT04720378View on ClinicalTrials.gov

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 30, 2021

Primary Completion Date

May 3, 2022

Study Completion Date

May 3, 2022

Conditions
Cytokine Release Syndrome
Interventions
BIOLOGICAL

ST266

1X ST266

Trial Locations (3)

33756

Innovative Research of West Florida, Clearwater

37421

WR-ClinSearch, LLC, Chattanooga

60640

Great Lakes Clinical Trials, Chicago

Sponsors

Collaborators (1)

IQVIA Biotech
All Listed Sponsors
collaborator

IQVIA Biotech

INDUSTRY

lead

Noveome Biotherapeutics, formerly Stemnion

INDUSTRY